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Background: Colorectal cancer (CRC) progression is associated with suppression of host cell-mediated immunity and local
immune escape mechanisms. Our aim was to assess the immune function in terms of expression of TNF, IFNG and FOXP3 in CRC.
Methods: Sixty patients with CRC and 15 matched controls were recruited. TaqMan quantitative PCR and methylation-specific
PCR was performed for expression and DNA methylation analysis of TNF, IFNG and FOXP3. Survival analysis was performed over
a median follow-up of 48 months.
Results: TNF was suppressed in tumour and IFNG was suppressed in peripheral blood mononuclear cells (PBMCs) of patients
with CRC. Tumours showed enhanced expression of FOXP3 and was significantly higher when tumour size was 438mm
(median tumour size; P¼ 0.006, Mann–Whitney U-test). Peripheral blood mononuclear cell IFNG was suppressed in recurrent
CRC (P¼ 0.01). Methylated TNFpromoter (P¼ 0.003) and TNFexon1 (P¼ 0.001) were associated with significant suppression of
TNF in tumours. Methylated FOXP3cpg was associated with significant suppression of FOXP3 in both PBMC (P¼ 0.018) and
tumours (P¼ 0.010). Reduced PBMC FOXP3 expression was associated with significantly worse overall survival (HR¼ 8.319,
P¼ 0.019).
Conclusions: We have detected changes in the expression of immunomodulatory genes that could act as biomarkers for
prognosis and future immunotherapeutic strategies.
Patients with colorectal cancer (CRC) are likely to be immuno-
suppressed due to a number of factors including older age (Pawelec
et al, 2002) and poor nutritional status (Grunfeld, 2002). However,
CRC itself has a direct suppressive effect on the cell-mediated
immunity (CMI) as demonstrated by studies showing resolution of
normal immunological function after successful tumour resection
(Heriot et al, 2000; Galizia et al, 2002). A shift in immune function
has been demonstrated in patients with CRC. Decreased total
numbers of TH1 CD4þ cells have been found in patients with
CRCs (Nakayama et al, 2000). There is also reduced production of
cytokines from TH1 lymphocytes(TNF-a and IFN-g) while those
produced by TH2 lymphocytes appear to remain at normal or even
elevated levels (O’Hara et al, 1998; Heriot et al, 2000; Shibata et al,
2002; Kanazawa et al, 2005). TNF-a and IFN-g levels were shown
to be particularly low in CRC with vascular invasion (Evans
et al, 2010).
Tumour necrosis factor-a (TNF-a) is a TH1 cytokine with both
pro- and anti-cancer properties. Multiple experiments have shown
that TNF-a produced chronically at low picogram levels in the
tumour microenvironment, whether by tumour or stromal cells
(or most likely both) may cause direct DNA damage, may have
anti-apoptotic or mitogenic activity, may mediate tumour/stromal
cell interactions and induce a range of matrix metalloproteinases,
cytokines and chemokines that promote tumour development
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(Balkwill, 2006). Activation of regulatory T cells (Tregs) can cause
immunosuppression and has resulted from prolonged exposure to
TNF-a (Chen et al, 2007), which could have a cancer promoting
effect. On the contrary, in vivo recombinant TNF-a directly
injected into tumours destroys the tumour vasculature (Watanabe
et al, 1988). Genetically engineered tumour cells producing high
levels of TNF-a have been implanted into tumours and, although
they do not kill the tumours, they inhibit the growth through the
activation of macrophages and natural killer cells (Blankenstein
et al, 1991). Heriot et al (2000) have shown a highly significant
reduction in production of TNF-a and IFN-g (interferon-g) by
lipopolysachharide (LPS) stimulated whole-blood cultures derived
from patients with CRC as compared to similarly aged controls.
They had also shown that suppression of TNF-a and IFN-g
production was higher in late-stage tumours compared to early-
stage tumours and this disappears following the resection of
tumour. A subsequent follow-up study confirmed that patients
who had lower levels of TNF-a and IFN-g had significantly worse
survival (Evans et al, 2006).
T-regulatory cells are implicated in the development of
autoimmunity, allergy and rejection of organ transplants, as well
as the suppression of immune responses to cancer. There is an
increased presence of CD4þCD25þ T cells in a wide spectrum of
human malignancies, such as lung, head and neck, ovarian,
gastrointestinal and skin. These cells are found in relatively high
concentrations in blood, ascites, tumour draining lymph nodes and
within the tumour milieu of cancer patients. Regulatory T cells
were initially characterised by the CD4þCD25þ phenotype and
are thought to modulate the antitumour immune response
(Zou, 2006; Curiel, 2007). Depletion of intratumoural Tregs was
found to enhance antitumour immunity and tumour rejection in
mouse models (Needham et al, 2006). Loddenkemper et al (2006)
reported that Treg density in human CRC was lower in node-
positive disease but was not associated with survival. However,
Ling et al (2007) found no significant difference in Treg density
between advanced- and early-stage disease.
The most specific Treg-cell marker identified is the nuclear
transcription factor known as FOXP3 (Fontenot et al, 2003; Hori
et al, 2003). A high density of tumour-infiltrating FOXP3þ Tregs
has been associated with poor outcome in various solid tumours,
including ovarian (Curiel et al, 2004; Sato et al, 2005), pancreatic
(Hiraoka et al, 2006) and hepatocellular carcinoma (Kobayashi
et al, 2007). The expression of FOXP3 in naive CD4þ T cells has
been shown to decrease IFN-g and IL-2 secretion and leads to
increased expression of other receptors, which are characteristic of
Tregs, such as CD25, glucocorticoid-induced TNF receptor and
cytotoxic T Lymphocytic Antigen 4 (Hori et al, 2003). The
importance of FOXP3 in functioning Tregs is now well established
and is thought to be induced by TCR activation in conjunction
with TGF-b stimulation (Coffer and Burgering, 2004). Moreover,
FOXP3 expression has also been seen in tumour cells, which may
also provide tumours with direct immunosuppressive powers
(Hinz et al, 2007; Ebert et al, 2008). The Tregs downregulating
tumour-specific immunity is particularly prominent in solid
tumours such as colorectal carcinoma (Curiel et al, 2004).
FOXP3 expression mediated by cancer cells have been shown to
contribute towards disease progression in CRC (Kim et al, 2013).
As FOXP3 is a crucial regulator of T regs, compounds that inhibit
the expression, function and signalling of FOXP3 might have
therapeutic potential.
Published reports from our department have demonstrated the
significance of TNF-a and IFN-g levels in CRC (Heriot et al, 2000;
Evans et al, 2006; Evans et al, 2010). In line with the literature
(Somasundaram et al, 2002; Wolf et al, 2003) unpublished research
in our department has shown increased numbers of Treg cells in
CRC. With a view to take these findings forward, our aim was to
assess the immune function in terms of the expression of TNF,
IFNG and FOXP3 in peripheral blood and tumour of patients with
CRC. We also aimed at assessing the influence of DNA methylation
on the expression of the study genes, which would be helpful in
identifying a potential role for epigenetic regulation in CRC.
MATERIALS AND METHODS
A total of 60 patients with a diagnosis of colorectal adenocarci-
noma were recruited into the study following approval by the local
research ethics committee (South West London REC 3, UK).
Peripheral blood mononuclear cells (PBMCs) were separated from
venous blood using Ficoll–Hypaque density gradient method. Total
RNA and DNA were isolated from the PBMCs, fresh frozen
tumour tissue and normal mucosa (Qiagen AllPrep DNA/RNA
Mini kit and QIAshredder), and simultaneous purification of
genomic DNA and total RNA was performed from a single
biological sample. The total RNA and DNA extracted from all the
samples were analysed for quantity and quality using the
NanoDrop spectrophotometer. RNA and DNA extraction were
repeated for samples that did not meet the manufacturer’s
recommendations. The samples that were not satisfactory for
either quantity or quality during repeat extraction were excluded
from the analysis.
TaqMan quantitative PCR (qRT-PCR, two step) was used to
determine the relative fold change in the expression of TNF, IFNG
and FOXP3 in the PBMC (compared to controls) and tumour
(compared to normal mucosa), with GAPDH as internal control. The
total RNA isolated was reverse transcribed into cDNA using the High
Capacity cDNA Reverse Transcription kit (Applied Biosystems, Foster
City, CA, USA). Predesigned TaqMan Gene Expression Assays
(Applied Biosystems) for the test (assay ID: Hs00174128_m1 – TNF,
Hs00989291_m1 – IFNG, Hs01085834_m1 – FOXP3) and
reference gene (GAPDH) were obtained from Applied Biosystems.
Quantitative analysis of the PCR products were performed using
the ABI 7500 Fast Real-time PCR system (Applied Biosystems).
Relative quantification of gene expression was performed using the
2DDCt method (Livak and Schmittgen, 2001).
Methylation-specific PCR (MSPCR) was performed to identify
the methylation status of the study genes. EZ-96 DNA Methyla-
tion-Gold kit (Zymo Research, Irvine, CA, USA) was used for the
bisulfite conversion of DNA. Subsequently a multiplex PCR was
performed. Each 15ml MSPCR included 7.5 ml Qiagen Multiplex
Master Mix (Qiagen, Hilden, Germany) consisting of HotStarTaq
DNA polymerase (Qiagen), multiplex PCR buffer, Mg2þ and
dNTPs at optimum concentration; 3 ml Q solution (Qiagen), 0.3 ml
each of forward and reverse primers, 2.9 ml of RNAse-free water
and 1 ml of bisulfite-converted template DNA. All PCRs were
undertaken in 96-well PCR plates (ABgene, Thermo Scientific,
Waltham, MA, USA). The PCR conditions were hot-start step of
951C for 15min, followed by a 35-cycle programme consisting of
941C for 60 s, 601C for 90 s, 721C for 1min followed by final 721C
for 10-min extension step. The primer sequences used in the
MSPCR are enumerated in Table 1. MSPCR products were
analysed on agarose gel electrophoresis. Methyltransferase-treated
and -untreated DNA was used as controls for methylated and
unmethylated DNA. Samples were defined as methylated or
unmethylated depending upon the visual band amplified with
methylated or unmethylated primers. Microsatellite instability
(MSI) status of the tumour samples were analysed by PCR using
microsatellite primers BAT25 and BAT26.
The control group included 15 matched patients who attended
colorectal clinic with benign colorectal disease and underwent
investigations, which ruled out CRC. The control group was used
only for the comparison of expression of study genes in PBMC
samples. All data analyses were performed using the SPSS 19.0
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software (SPSS, Chicago, IL, USA). Pearson’s chi-square analysis
and Fisher’s exact test were employed to compare the difference of
categorical variables between patient groups. The relative gene
expression levels were compared between various subgroups using
Kruskal–Wallis test (42 groups) and Mann–Whitney U-test (two
groups). Survival was analysed according to Kaplan–Meier
method. Significance was assumed when the statistical tests
returned P-values o0.05.
RESULTS
The study group included 60 patients (32 males, 28 females);
68% (n¼ 41) of patients had left-sided tumours (at or distal to
splenic flexure), which were predominantly rectal (n¼ 27). Two
patients had synchronous tumours in the rectum and sigmoid
colon. The study group included seven patients with recurrent
cancers, the sites of which included rectum (n¼ 5), caecum (n¼ 1)
and left paracolic space (n¼ 1). Tumour size varied from 5 to
140mm (mean 44.8, median 38 and s.d. 23.1). Tumour VI was
present in 32% (n¼ 18) of our patients and 18% (n¼ 11) had poor
differentiation. The TNM staging distribution of patients with
primary CRC was – stage 1 (n¼ 9), stage 2 (n¼ 22), stage 3
(n¼ 18) and stage 4 (n¼ 4). Among the patients with recurrent
CRC (n¼ 7) the primary staging distribution was – stage 2 (n¼ 3),
stage 3 (n¼ 1) and stage 4 (n¼ 3). Supplementary Table 1
enumerates the patient and tumour characteristics.
Gene expression – qRT-PCR. The gene expression levels as
measured by the relative quantification method for our study genes
are enumerated in Table 2. Gene expression levels are relative to
GAPDH expression where GAPDH expression level is equal to 1.
Although the median expression levels of the TNF in the PBMC
samples were close to reference level (median 0.89), the TNF was
found to be suppressed in the tumour samples (median 0.48).
On the contrary IFNG was found to be suppressed in the PBMC
samples (median 0.34), but the expression levels in the tumour
samples were close to the reference level (median 1.21). Although
the expression levels of FOXP3 were reduced in the PBMC samples
(median 0.24), increased expression was seen with tumour samples
(median 2.20).
Gene expression and tumour characteristics. Although the
expression of TNF in tumours were suppressed as mentioned
above, the suppression was found to be maximum in stage 4
tumours and was statistically significant (P¼ 0.04; Figure 1A). No
significant difference was noticed with respect to TNF expression
in the PBMC based on stage. However, significant suppression of
the PBMC IFNG was noticed in stage 4 tumours (P¼ 0.01;
Figure 1B). TNF expression in the tumour samples was
significantly high in patients with VI (P¼ 0.034; Supplementary
Figure 1). IFNG suppression was significant in the recurrent CRC
group compared to the primary CRC group (P¼ 0.01;
Supplementary Figure 2). FOXP3 expression in tumours was
found to be high in stage 3 tumours, however, the enhanced
expression approached but did not reach statistical significance
(P¼ 0.06). Although there was an enhanced expression of FOXP3
in tumours, a significantly increased expression was particularly
noticed in large-sized tumours (438mm, median tumour
size¼ 38mm, P¼ 0.006; Figure 2). A significant positive correla-
tion was noticed in the expression levels of TNF and IFNG in both
PBMC (P¼ 0.001) and tumours (P¼ 0.006). The gene expression
levels did not have any significant association with grade of CRC.
DNA methylation and gene expression. Samples were defined as
methylated or unmethylated depending upon the visual band
amplified with methylated or unmethylated primers (Figure 3).
The methylation status and expression levels with respect to the
study genes are enumerated in Table 3. TNF methylation was
examined at the promoter region and the first exon. TNF
expression levels were analysed in the two subgroups (methylated
and unmethylated). A significant difference was observed in
tumour samples with lower expression found in the methylated
group compared to the unmethylated group at both TNFpromoter
(P¼ 0.003) and TNFexon1 (P¼ 0.001) sites. The TNF expression
in the PBMC samples did not have a significant association with
methylation status. The DNA methylation status of TNFpromoter
and first exon in both tumours and PBMC did not have any
significant association with other pathological prognostic factors.
IFNG promoter methylation was observed in 65% of PBMC
samples and 55% of tumour samples in patients with CRC. There
was no significant difference observed in the expression levels
between the methylated and unmethylated groups. There was no
Table 2. The gene expression levels relative to GAPDH in our study
samples
Median
fold change Range 
P value
(mann-whitney)
TNF PBMC 0.89 0.908
TNF tumour 0.48 0.005
IFNG PBMC 0.34 <0.001
IFNG
tumour 1.21 0.613
FOXP3
PBMC 0.24 <0.001
FOXP3
tumour 2.20 0.043
0.05–82.87 
0.01–14.48
0.02–23.55
0.04–57.63
0.07–33.53
0.05–79.73
Abbreviation: PBMC¼peripheral blood mononuclear cell. Bold indicates statistically
significant values.
Table 1. The primer sequences used for MSPCR, obtained from Sigma-
Aldrich
Name Sequence
TAGAAGGTGTAGGGTTTATTATCGT
TACCTTTATATATCCCTAAAACGAA
TAGAAGGTGTAGGGTTTATTATTGT
TACCTTTATATATCCCTAAAACAAA
GAGTATTGAAAGTATGATTCGGGAC
CAACAAACAAAAAAACGTAATAACG
GTATTGAAAGTATGATTTGGGATGT
ACAAACAAAAAAACATAATAACACC
GTGGGTATAATGGGTTTGTTTTATC
AATTAAAATCTCCTAAAAATTACGTA
GGTATAATGGGTTTGTTTTATTGT
AATTAAAATCTCCTAAAAATTACATA
GTAAAGGGTAGTTGGAAGGTAAAGC
GTACGAACCTCACACGACGA
TAAAGGGTAGTTGGAAGGTAAAGTG
TACACATACAAACCTCACACAACAA
AGAGGTTTAAAAAGTGGGAGATTTC
ATTAACTCGCTACAACCATTATCGT
AGAGGTTTAAAAAGTGGGAGATTTT
TTAACTCACTACAACCATTATCATC
TNF-pr-Meth-F
TNF-pr-Meth-R
TNF-pr-Unmeth-F
TNF-pr-Unmeth-R
TNF-ex-Meth-F
TNF-ex-Meth-R
TNF-ex-Unmeth-F
TNF-ex-Unmeth-R
IFNg-Meth-F
IFNg-Meth-R
IFNg-Unmeth-F
IFNg-Unmeth-R
FOXP3-enc-Meth-F
FOXP3-enc-Meth-R
FOXP3-enc-Unmeth-F
FOXp3-enc-Unmeth-R
FOXP3-CpG-Meth-F
FOXP3-CpG-Meth-R
FOXP3-CpG-Unmeth-F
FOXP3-CpG-Unmeth-R
Abbreviations: enc¼ enhancer; ex¼exon1; F¼ forward; Meth¼methylated; pr¼promoter;
R¼ reverse; Unmeth¼ unmethylated.
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significant association between the methylation status of the IFNG
and the relative IFNG expression level. The methylation status of
IFNG in both PBMC and tumour samples did not have any
significant association with any of the pathological prognostic
indicators.
FOXP3 methylation was analysed at enhancer and CpG island
sites. FOXP3cpg methylation was observed in 70% of PBMC
samples and 39% of tumour samples in patients with CRC. FOXP3
relative expression levels were analysed in the two subgroups
(methylated and unmethylated). There was a significant difference
in the levels of FOXP3 expression with lower expression in the
methylated group in both PBMC (P¼ 0.001) and tumour samples
(P¼ 0.010). FOXP3enc methylation status was not associated with
significant difference in the expression levels. There was no
correlation noted with FOXP3 methylation status and tumour size
even though the tumour size correlated with relative FOXP3
expression.
Microsatellite instability status, gene expression and DNA
methylation. Microsatellite instability status was analysed in 47
patients in our study; 19% (9 of 47, 4 males) of patients in our
study were found to have MSI. Although 14% of males with CRC
were found to have tumours positive for MSI, 26% of females were
found to be positive for MSI. However, the difference was not
statistically significant; 9% (4 of 47) were found to have MSI at
both BAT25 and BAT26 loci, while the other five patients were
positive in either of the two loci. Significant TNF suppression
(P¼ 0.002) was noted in the PBMC samples of patients with MSI
compared to patients who were microsatellite stable (MSS;
Supplementary Figure 3). However, the TNF expression in the
tumour samples did not correlate with MSI status. There was no
significant difference noted in the expression of IFNG and FOXP3
between MSI and MSS patients. There was also no correlation
observed between the MSI status and DNA methylation status of
our study genes.
Survival analysis. During a median follow-up period of 48
months a total of 23 patients died. Among the patients who
underwent curative resection of CRC, 14 patients developed
recurrent disease. In order to analyse the survival based on relative
gene expression, patients were classified into two groups based on
the median expression level. Patients who had higher FOXP3
expression in the PBMC samples had a significantly better overall
survival (OS) compared to patients with lower FOXP3 expression
(P¼ 0.022, log-rank test; Figure 4A). Similarly, patients with higher
PBMC FOXP3 expression had a significantly better recurrence-free
survival (RFS, P¼ 0.001; Figure 4B). There was no significant
difference in OS and RFS noted with respect to the expression
of TNF and IFNG in both PBMC and tumour samples.
On multivariate Cox regression analysis (Table 4) PBMC FOXP3
expression was found to be a significant factor influencing the OS
(HR¼ 8.319, P¼ 0.019; Supplementary Figure 4) and to a lesser
extent the RFS (HR¼ 5.106, P¼ 0.173).
DISCUSSION
The median expression levels of the genes TNF (median 0.48) and
IFNG (median 0.34) were found to be low in the tumour and
PBMC samples, respectively. It has been demonstrated in the past
that the production of TNF-a and IFN-g by LPS stimulated whole-
blood cultures derived from patients with CRC are reduced as
compared to controls (Heriot et al, 2000). It was also shown that
the suppression of TNF-a and IFN-g cytokine production was
higher in the late stages than the earlier stages of CRC. In this
study, we have shown that the suppression of TNF-a cytokine
levels is likely to be due to the suppression of TNF gene in the
tumour microenvironment rather than systemic. However, low
levels of IFNG expression was noted in the PBMC samples in our
study, which indicate that the site of IFNG suppression is likely to
be systemic rather than in the tumour microenvironment.
Although no specific pattern with TNF and IFNG suppression
was noted with respect to stages 1–3 CRC, suppression was found
to be statistically significant in stage 4 disease. Although it is
possible that immune suppression as represented by the reduced
levels of expression of CMI-associated cytokine genes TNF and
IFNG could be the reason behind progression of the disease to
stage 4, this study is able to establish the correlation but unable to
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Figure 1. (A and B) Levels of TNF and IFNG expression significantly reduced in stage 4 disease in tumour and PBMC samples, respectively
(36, 59 and 45 indicate outlier sample numbers).
25.00
20.00
15.00
10.00
FO
XP
3 
tu
m
ou
r f
ol
d 
ch
an
ge
5.00
0.00
Size < 39 mm Size > 38 mm
Tumour size
26
33
57
Figure 2. Levels of expression of FOXP3 in tumour tissue was
significantly enhanced in large tumours (438mm, median tumour
size) (26, 33 and 57 indicate outlier sample numbers).
BRITISH JOURNAL OF CANCER Immune function and colorectal cancer
1584 www.bjcancer.com |DOI:10.1038/bjc.2014.477
confirm the cause and effect relationship. Similar to stage 4 disease,
presentation of patients with recurrent disease following previous
resection also represents disease progression. We also noticed that
the expression levels of IFNG in the PBMC samples were
significantly low in recurrent CRC. The early evidence for
antitumour effect of IFNs came from carcinogenesis experiments
employing mice that lack IFN-g, where spontaneous tumour
development was more frequent and rapid as compared to wild-
type mice. Interferon-g is an important antiproliferative cytokine
that is involved in multiple pathways to check the tumour
progression (Brandacher et al, 2006). It is possible that immuno-
suppression in the form of low IFN-g levels could have contributed
S1M S2M S3M S4M S5M S6M S7M S8M S1U S2U S3U S4U S5U S6U S7U S8U
Figure 3. Agarose gel electrophoresis demonstrating the MSPCR products for a series of eight tumour samples with TNF methylated primers on
the left and TNF unmethylated primers on the right of 100bp ladder. Although the first seven samples showed methylated product, sample 8
showed unmethylated product. Abbreviations: S1M¼ sample 1 methylated; S1U¼ sample 1 unmethylated.
Table 3. The methylation status of samples illustrated at various sites
Site Sample Methylation status P value
TNFpromoter PBMC 0.561
TNFpromoter Tumour 0.003
TNFexon1 PBMC 0.894
TNFexon1 Tumour 0.001
IFNGpromoter PBMC 0.533
IFNGpromoter Tumour 0.176
FOXP3cpg PBMC
FOXP3cpg Tumour 0.010
FOXP3enc PBMC
FOXP3enc Tumour 0.054
0.69(0.06–82.87)
Expression
median(min-max)
0.001
0.051
1.23(0.32–14.89)
0.31(0.02–10.44)
1.87(0.56–14.48)
0.83(0.06–82.87)
1.03(0.36–16.26)
0.24(0.02–1.55)
2.18(0.48–14.48)
0.14(0.01–23.56)
0.87(0.02–11.82)
0.61(0.01–30.55)
2.73(0.55–157.63)
0.16(0.01–0.55)
0.52(0.15–33.53)
0.72(0.01–20.75)
9.86(0.01–78.21)
0.25(0.01–0.55)
0.36(0.01–33.53)
0.72(0.01–20.75)
6.76(0.01–78.21)
M – 55%
U – 45%
M – 67%
U – 33%
M – 59%
U – 41%
M – 67%
U – 33%
M – 65%
U – 35%
M – 55%
U – 45%
M – 70%
U – 30%
M – 39%
U – 61%
M – 67%
U – 33%
M – 37%
U – 63%
Abbreviation: PBMC¼peripheral blood mononuclear cell. The expression levels of methylated and unmethylated samples are compared (Independent samples test; M-Methylated,
U-Unmethylated).
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to the recurrence of CRC. We feel that the disease progression in
the form of recurrent disease in CRC is likely to be due to the
systemic immune suppression as represented by low IFNG
expression in PBMC. We have demonstrated a significant positive
correlation between the expression of TNF and IFNG, reiterating
the fact that both these cytokines act through TH1 pathways that
are associated with immune deviation towards enhanced or
suppressed tumour rejection based on their activity.
Vascular invasion is seen as one of the discrete steps in the
metastatic cascade and results in tumours being capable of
shedding millions of tumour cells into the vascular circulation
(Liotta et al, 1974). Vascular invasion has been shown to be an
independent predictor for haematogenous disease recurrence and
decreased survival in CRC (Talbot et al, 1980; Harrison et al, 1994;
Petersen et al, 2002; Morris et al, 2006; Quirke and Morris, 2007;
Sato et al, 2010). We found that the expression of TNF in tumours
was significantly high in the presence of VI. An earlier study found
that serum levels of TNF-a was significantly low in the presence of
VI (Evans et al, 2010). It is possible that the presence of VI leads to
systemic tumour exposure and may explain the significant fall in
systemic TH1 cytokine production. Increased expression of TNF in
the tumours with VI in our study could be a manifestation of
cancer promoting effect of TNF. It is well known that TNF-a is a
TH1 cytokine with both pro- and anticancer properties. In prostate
cancer, TNF has been shown to enhance the in vitro migration and
invasion of tumour cells through increasing the expression of
several glycosyl- and sulfo-transferase genes that are involved in
the synthesis of mucin-type selectin ligands (Radhakrishnan et al,
2011). As a result, TNF enhanced the entry of tumour cells into the
bloodstream.
DNA methylation is an important regulator of gene transcrip-
tion, and its role in carcinogenesis has been a topic of considerable
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Figure 4. (A and B) Kaplan–Meier survival curves for OS (P¼ 0.022, A) and RFS (P¼ 0.001, B) in patients classified based on the median
expression levels of PBMC FOXP3. Abbreviation: Cum¼ cumulative.
Table 4. Multivariate Cox regression analysis of various factors influencing the OS
B SE Sig HR 95% CI for exp(B) 
Lower Upper 
Age -0.864 0.651 0.184 0.421 0.118 1.508
Stage 1.473 1.012 0.145 4.363 0.030 3.275
T status –1.154 1.194 0.334 0.316 0.577 21.120
N status 1.251 0.918 0.173 3.492 0.162 4.463
Grade 0.846 0.848 0.850 0.080 1.704
Vascular invasion 0.780 0.202 0.370 1.415 48.917
2.119 0.904 0.019 8.319 0.601 31.684PBMC FOXP3
expression
–0.995
–0.162
Abbreviations: B¼ regression coefficient; CI¼ confidence interval; exp(B)¼ hazard ratio; HR¼ hazard ratio; PBMC¼peripheral blood mononuclear cell; SE¼ standard error; Sig¼ significance.
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interest in the last few years. It is currently well known that cancer
is characterised by a tremendous amount of epigenetic aberrations,
and hence it could be postulated that these aberrations could have
an influence on the immune genes in cancer. Hence the DNA
methylation status was analysed in our samples in order to
correlate it with the expression levels. The significantly lower
expression of TNF in methylated tumours illustrates a likely role of
DNA methylation in silencing the TNF gene in CRC. Through
CRC cell-line experiments Sullivan et al (2007) had shown the
possibility of a direct role for DNA methylation in the regulation of
TNF-a expression. The influence of DNA methylation on the
expression of TNF in human CRC has not been studied in the past.
However, we did not find a significant correlation between the
methylation status of the IFNG and the relative IFNG expression
level. A strong correlation was observed in the DNA methylation
status and expression of FOXP3 in both PBMC and tumour
samples. With the help of murine experiments Polansky et al
(2008)had shown that DNA methylation in T-regulatory cell-
specific demethylated region not only regulates FOXP3 gene
transcription, but also is critically involved in maintaining stable
FOXP3 expression. Hence our finding of a strong correlation
illustrates the possible role for DNA methylation in the regulation
of FOXP3 in human CRC.
Over the past few decades it has become clear that CRC evolves
through multiple pathways and that these pathways can be roughly
defined on the basis of molecular patterns such as the integrity of
the mismatch repair system or mutational and epigenetic patterns.
Tumours with MSI have greater numbers of tumour-infiltrating
lymphocytes that are activated and cytotoxic (Phillips et al, 2004)
and the lymphocytic reaction is independently associated with
longer survival (Ogino et al, 2009). Hence, we classified the patients
based on their MSI status in order to observe any difference in the
prognosis, gene expression and methylation levels in the two
subgroups. In comparison with MSS group, MSI group had a
significantly reduced expression of TNF in the PBMC samples.
Although the MSI tumours are known to be immunogenic, such a
finding has not been reported in the past and could represent a specific
form of immune response in CRC. However, DNA methylation
and survival did not correlate with MSI status in our study.
A high density of tumour-infiltrating FOXP3þ Tregs has been
demonstrated to be associated with a poor outcome in a wide
variety of malignancies including CRC (Curiel et al, 2004; Sato
et al, 2005; Hiraoka et al, 2006; Kobayashi et al, 2007). Other
studies have shown that it may be associated with favourable
prognosis (Salama et al, 2009). The T-regulatory cells that are
characterised by the expression of FOXP3 have been shown to be
capable of inhibiting tumour-associated antigen-specific immune
responses in patients with CRC (Clarke et al, 2006). A significantly
increased expression of FOXP3 by CRC cells has been demon-
strated and was also found to be associated with poor prognosis
(Kim et al, 2013). We have demonstrated that the FOXP3 mRNA
expression is enhanced in the tumour tissue. The expression was
significantly higher in large-sized tumours (classified based on
median tumour size). Hence, the expression of FOXP3 can be
considered to be associated with tumour growth and hence tumour
progression. FOXP3 expression in tumour cells was found to be a
strong predictor of metastatic disease and lymph node positivity in
a study of human breast cancer patients (Merlo et al, 2009). FOXP3
expression was also found to correlate with stage and lymph node
metastasis in oesophageal squamous cancer (Xue et al, 2010).
However, a differential expression of FOXP3 in tumour tissue with
respect to tumour size has not been demonstrated in the past. In our
study, we have also clearly demonstrated that higher FOXP3
expression in the PBMC was associated with significantly better OS
and RFS. The significance of its association with better OS was also
confirmed on multivariate Cox regression analysis. This finding could
add to the prognostic significance of FOXP3 expression in CRC.
Although MSPCR is a rapid and reliable measure of the
methylation status in CpG island, the limitation is that it is not
quantitative. Having identified a strong association of DNA
methylation in the expression of TNF and FOXP3 this could be
taken forward by performing quantitative analysis with bisulfite
pyrosequencing and demethylation experiments. Increased expres-
sion of FOXP3 noted with respect to increasing size of the tumours
will need to be confirmed with immunohistochemical studies.
Considering the prognostic importance of FOXP3 expression
identified in our study further exploration of the canonical
pathways of FOXP3 transcription in CRC will be necessary in
the future.
CONCLUSION
Although it is already known that suppression of CMI is a feature
in almost all cancers, our study has demonstrated specific
alterations in the expression and methylation of CMI-associated
immune genes that may offer novel immunomodulatory
approaches in the management of CRC. We have demonstrated
a possible role for cytokine genes TNF and IFNG in the CRC
progression, with specific patterns of suppression noted in stage 4
and recurrent CRC. FOXP3 appears to have a specific role in the
progression of the primary tumour due to its association noted
with tumour size. We have clearly demonstrated survival benefit in
patients with higher PBMC FOXP3 expression. In addition, we
have shown that DNA methylation could play an important role in
the regulation of TNF and FOXP3. Our novel findings will need
further confirmation with the help of quantitative and pathway
analyses.
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